Change in Expression of ER, bcl-2 and MIB1 on Primary Tamoxifen and Relation to Response in ER Positive Breast Cancer

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Breast Cancer Research and Treatment

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1023/A:1006469627067PMID 11261829
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells

  2006cited by this paper
• Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cancer cells

  2004cited by this paper
• Clinical significance of bcl-2 gene expression in human breast cancer tissues

  2004cited by this paper
• Gamma linolenic acid with tamoxifen as primary therapy in breast cancer

  1998cited by this paper
• Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response

  1998cited by this paper
• The expression of Ki-S1 and BCL-2 and the response to primary tamoxifen therapy in elderly patients with breast cancer

  1997cited by this paper
• Duration of remission to ICI 182,780 compared to megestrol acetate in tamoxifen resistant breast cancer

  1997cited by this paper
• bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study.

  1997cited by this paper
• pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients.

  1996cited by this paper
• Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer.

  1996cited by this paper
• Short-term effects of pure anti-oestrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factor-alpha protein expression in human breast cancer.

  1996cited by this paper
• Oestrogen and Progesterone Receptors as Prognostic Variables in Hormonally Treated Breast Cancer

  1996cited by this paper
• Oestrogen receptor: a stable phenotype in breast cancer.

  1996cited by this paper
• Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes

  1996cited by this paper
• Use of tamoxifen for breast cancer: twenty-eight years later.

  1995cited by this paper
• Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells

  1995cited by this paper
• Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer.

  1995cited by this paper
• Mechanisms of hormone response: a role for apoptosis

  1995cited by this paper
• Apoptosis suppressing protein bcl‐2 is expressed in well‐differentiated breast carcinomas with favourable prognosis

  1995cited by this paper
• Bcl-2 protein expression in breast cancer in relation to established prognostic factors and other clinicopathological variables.

  1995cited by this paper
• The bcl-2 proto-oncogene and the gastrointestinal epithelial tumor progression model.

  1995cited by this paper
• Prognostic value of bcl-2 expression in invasive breast cancer.

  1995cited by this paper
• A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples.

  1995cited by this paper
• Bcl-2 and the regulation of programmed cell death

  1994cited by this paper
• Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer.

  1994cited by this paper
• Modulation of Bcl-2 and Ki-67 expression in oestrogen receptor-positive human breast cancer by tamoxifen.

  1994cited by this paper
• bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer.

  1994cited by this paper
• Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer.

  1994cited by this paper
• Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity.

  1994cited by this paper
• Immunocytochemical localization of fos protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy

  1994cited by this paper
• Immunocytochemical localization of BCL‐2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy

  1994cited by this paper
• Pure antioestrogens in breast cancer - experimental and clinical observations

  1994cited by this paper
• Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification.

  1993cited by this paper
• Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration.

  1993cited by this paper
• Methodology of immunohistological detection of oestrogen receptor in human breast carcinoma in formalin‐fixed, paraffin‐embedded tissue: a comparison with frozen section methodology

  1993cited by this paper
• Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status.

  1993cited by this paper
• Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer.

  1992cited by this paper
• Monoclonal antibodies against recombinant parts of the Ki‐67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave‐processed formalin‐fixed paraffin sections

  1992cited by this paper
• Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study.

  1992cited by this paper
• Hormone sensitivity in breast cancer: influence of heterogeneity of oestrogen receptor expression and cell proliferation.

  1991cited by this paper
• Cellular effects of tamoxifen in primary breast cancer

  1991cited by this paper
• A potent specific pure antiestrogen with clinical potential.

  1991cited by this paper
• Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: comparison with quantitative biochemical methods.

  1989cited by this paper
• Induction of progesterone receptor with tamoxifen in human breast cancer with special reference to its behavior over time

  1988influential reference
• Prediction of endocrine response in breast cancer by immunocytochemical detection of oestrogen receptor in fine-needle aspirates.

  1987cited by this paper
• Endocrine therapy for advanced carcinoma of the breast: relationship between the effect of tamoxifen upon concentrations of progesterone receptor and subsequent response to treatment.

  1987influential reference
• Increase of progesterone receptor by tamoxifen as a hormonal challenge test in breast cancer.

  1980cited by this paper
• IN SEARCH OF THE SOMOGYI EFFECT

  1980cited by this paper
• Assessment of response to therapy in advanced breast cancer. A project of the programme on clinical oncology of the International Union against Cancer, Geneva, Switzerland.

  1978cited by this paper
• Assessment of response to therapy in advanced breast cancer.

  1977cited by this paper
• DRUG TREATMENT OF RHEUMATOID ARTHRITIS

  1975cited by this paper
• Assessment of response to treatment in advanced breast cancer. British Breast Group.

  1974cited by this paper
• ASSESSMENT OF RESPONSE TO TREATMENT IN ADVANCED BREAST CANCER

  1974cited by this paper

• Transcription of microRNAs is regulated by developmental signaling pathways and transcription factors

  2024cites this paper
• Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapy

  2021cites this paper
• Hormone Receptor Down-Regulation in Metastatic Breast Cancer After Endocrine Therapy Detected in Oophorectomy: A Case Report and Review of Literature

  2021cites this paper
• Markers of steroid receptor, kinase signalling pathways and Ki-67 expression in relation to tamoxifen sensitivity and resistance

  2020cites this paper
• A multicenter phase II trial of neoadjuvant letrozole plus low‐dose cyclophosphamide in postmenopausal patients with estrogen receptor‐positive breast cancer (JBCRG‐07): therapeutic efficacy and clinical implications of circulating endothelial cells

  2018cites this paper
• Epigenetic regulation of protein tyrosine phosphatase PTPN12 in triple-negative breast cancer.

  2015cites this paper
• Companion Diagnostics and Biomarkers BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer

  2013cites this paper
• BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer

  2013cites this paper
• Strength of ER-positivity in relation to survival in ER-positive breast cancer treated by adjuvant tamoxifen as sole systemic therapy.

  2011cites this paper
• Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer.

  2011cites this paper
• Antihormone induced compensatory signalling in breast cancer: an adverse event in the development of endocrine resistance

  2011cites this paper
• The effects of gefitinib in tamoxifen‐resistant and hormone‐insensitive breast cancer: A phase II study

  2010cites this paper
• Primary Endocrine Therapy for the Treatment of Early Breast Cancer in Older Women

  2010cites this paper
• Effects of CH4893237, a new orally active estrogen receptor downregulator, on breast cancer xenograft models with low serum estrogen levels.

  2009cites this paper
• BCL-2 family function in antiestrogen-resistant breast cancer cells

  2009cites this paper
• The dark side of antihormonal action in breast cancer

  2009cites this paper
• Description and Pre-clinical Validation of Dynamic Molecular Determinants of Sensitivity to Aromatase Inhibitors in Breast Cancer

  2008cites this paper
• CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome

  2008cites this paper
• Prognostic value of proliferation and apoptosis in breast cancer

  2008cites this paper
• Fulvestrant (Faslodex (cid:1) )—How to Make a Good Drug Better

  2007cites this paper
• Investigating the mechanism of enhanced cytotoxicity of HPMA copolymer-Dox-AGM in breast cancer cells.

  2007cites this paper
• Fulvestrant (Faslodex) -- how to make a good drug better.

  2007cites this paper
• Upregulation of MICA on high-grade invasive operable breast carcinoma.

  2007cites this paper
• Overexpression of c-Myc and Bcl-2 during progression and distant metastasis of hormone-treated breast cancer.

  2007cites this paper
• Pre-clinical validation of early molecular markers of sensitivity to aromatase inhibitors in a mouse model of post-menopausal hormone-sensitive breast cancer

  2007cites this paper
• Differential expression of Bcl‐2, Bcl‐XL and p53 in colorectal cancer

  2006cites this paper
• Dual/pan-HER tyrosine kinase inhibitors: focus in breast cancer.

  2006cites this paper
• Expression of Vascular Endothelial Growth Factor and Proliferation Marker MIB1 Are Influenced by Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer

  2005cites this paper
• Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer.

  2005cites this paper
• Small molecules with EGFR-TK inhibitor activity.

  2005cites this paper
• Proliferation marker Ki-67 in early breast cancer.

  2005cites this paper
• Neoadjuvant Endocrine Therapy

  2004cites this paper
• Tamoxifen: an emerging preventive.

  2004cites this paper
• Prognostic value of proliferation in invasive breast cancer: a review

  2004cites this paper
• A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers.

  2003cites this paper
• Clinicopathological study of the expression of hsp27, pS2, cathepsin D and metallothionein in primary invasive breast cancer.

  2003cites this paper
• Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen.

  2003cites this paper
• Measurement of proliferation marker Ki67 in breast tumour FNAs using laser scanning cytometry in comparison to conventional immunocytochemistry

  2003cites this paper
• Studies of the Potential Utility of Ki67 as a Predictive Molecular Marker of Clinical Response in Primary Breast Cancer

  2003cites this paper
• The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro.

  2003cites this paper
• On prognostic and treatment predictive factors in early stage breast cancer

  2002cites this paper
• Prognostic and Predictive Factors and Targets for Therapy in Breast Cancer

  2002cites this paper